Igor Aurer

The Genetic Basis of Hepatosplenic T-cell Lymphoma

Matthew McKinney, Andrea B. Moffitt, Philippe Gaulard et al. · Cancer Discovery · 2017 · 202 citations · Full text

Medicine, Genetics, Oncology +16

Dose Intensity of Chemotherapy in Patients With Relapsed Hodgkin's Lymphoma

Andreas Josting, Horst Müller, Peter Borchmann et al. · Journal of Clinical Oncology · 2010 · 162 citations · Full text

Medicine, Oncology, Pharmacology +15

Eight Cycles of ABVD Versus Four Cycles of BEACOPP_escalatedPlus Four Cycles of BEACOPP_baselinein Stage III to IV, International Prognostic Score ≥ 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup Trial

Patrice Carde, Matthias Karrasch, Catherine Fortpied et al. · Journal of Clinical Oncology · 2016 · 121 citations

Medicine, Oncology, Pharmacology +15

Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis

Massimo Federico, María Dolores Caballero Barrigón, Luigi Marcheselli et al. · The Lancet Haematology · 2018 · 116 citations · Full text

Medicine, Immunology, Oncology +9

FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk

Michele Spina, Zoltán Nagy, Josep‐María Ribera et al. · Annals of Oncology · 2015 · 89 citations · Full text

Medicine, Hematology, Pharmacotherapy +10